A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease-Reference-Cited by-同舟云学术

A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease

Published:2017-11 Issue:1 Volume:533 Page:298-314
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Wollmer Erik,Klein Sandra

Funder

Federal Ministry of Education and Research

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference183 articles.

1. Frequency of bowel movements and the future risk of Parkinson’s disease;Abbott;Neurology,2001

2. Constipation preceding Parkinson’s disease: a systematic review and meta-analysis;Adams-Carr;J. Neurol. Neurosurg. Psychiatry,2016

3. Electrogastrographyc activity in Parkinson’s disease patients with and without motor fluctuations;Albani;Mov. Disord.,2011

4. A study of salivary secretion in Parkinson’s disease;Bagheri;Clin. Neuropharmacol.,1999

5. Hyposalivation and xerostomia among Parkinson’s disease patients and its impact on quality of life;Barbe;Oral Dis.,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carboxymethyl chitosan dopamine conjugates: Synthesis and evaluation for intranasal anti Parkinson therapy;International Journal of Biological Macromolecules;2023-12

2. Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation;Molecular Pharmaceutics;2023-11-13

3. Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease;Scientific Reports;2023-09-22

4. Characterization of Aspirated Duodenal Fluids from Parkinson’s Disease Patients;Pharmaceutics;2023-04-14

5. Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease;2023-03-17